Hydroxyurea Decouples Persistent F-Cell Elevation and Induction of γ-Globin

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Fetal hemoglobin (HbF) levels are therapeutically relevant for sickle cell disease.
• Understanding the fetal-to-adult hemoglobin switch is crucial for developing new treatments.

Purpose of the Study:

• Investigate developmental γ-globin silencing in the Townes humanized knock-in mouse model.
• Evaluate the utility of this model for assessing pharmacologic induction of HbF.

Main Methods:

• Studied Townes mice (SS, AS, AA genotypes) from birth (P0) to 28 days (P28).
• Monitored F cell percentages and BCL11A expression.
• Administered hydroxyurea at different time points (P2 and P4).

Main Results:

• F cell percentages decreased from 100% at P0 to undetectable levels by P14 in untreated mice.
• γ-globin silencing was complete by P4, correlating with increased BCL11A expression.
• Hydroxyurea initiated at P2 sustained F cells at P14, but not when initiated at P4, suggesting erythropoiesis suppression rather than direct γ-globin reactivation.

Conclusions:

• The Townes mouse model accurately recapitulates the human postnatal γ- to β-globin switch.
• Hydroxyurea's myelosuppressive toxicity is a critical factor in interpreting HbF induction efficacy.
• This model provides insights into hemoglobin switching mechanisms and therapeutic interventions for hemoglobinopathies.